Moreover, CLEC7A exhibits a significant elevation in mesenchymal subtype gliomas, which are distinguished by heightened immunosuppression, increased aggressiveness, and malignant proliferation driven by mesenchymal differentiation resulting from mutations in the NF1 gene (11). This evidence concerns the gene CLEC7A and central nervous system cancer.